BiopharmaceuticalsNews and information about biopharmaceuticals.TVM Capital Announces Another Successful Exit in Its Life Science ... - Forbes- September 16, 2008 TVM Capital announced today the acquisition of DIREVO Biotech AG by Bayer HealthCare in an all cash deal at a transaction value of EUR 210 Million (approx. $300 Million). DIREVO Industrial Biotechnology GmbH, a wholly owned subsidiary of DIREVO ...http://www.forbes.com/businesswire/feeds/businesswire/2008/09/16/businesswire2008091600563... Danisco Divests Direvo Biotech AG to Bayer HealthCare - Food Ingredients First- September 16, 2008 160908 Direvo Biotech AG has announced the sale of its biopharmaceuticals business to Bayer HealthCare for EUR 210 million in an all cash deal.http://www.foodingredientsfirst.com/home/viewnews.rails?Id=18178&pageNo=1&isHome=T... DIREVO Biotech Acquired by Bayer HealthCare - Market Wire- September 16, 2008 COLOGNE, GERMANY--(Marketwire - September 16, 2008) - DIREVO Biotech AG announced today its acquisition by Bayer HealthCare in an all cash deal at a transaction value of EUR 210 Million (approx. $300 Million). DIREVO Industrial Biotechnology GmbH, a ...http://www.marketwire.com/press-release/Direvo-Biotech-Ag-900192.html Pall Corporation Fourth Quarter Sales Up 11.9% - Forbes- September 15, 2008 Fourth quarter sales grew to $723.2 million, an 11.9% increase over the fourth quarter of fiscal 2007. Diluted earnings per share ("EPS") were $0.57, up from $0.13 a year earlier. Net earnings were $69.9 million, compared to $16.8 million. Pro forma ...http://www.forbes.com/businesswire/feeds/businesswire/2008/09/15/businesswire2008091500672... Biovitrum Proffers $150M for Three Approved Biologics from Amgen - Genetic Engineering News- September 15, 2008 Biovitrum is paying Amgen $150 million upfront for three approved biopharmaceuticals. The deal covers the acquisition of Kepivance for cancer-related oral mucositis and Stemgen, given during peripheral blood progenitor cells (PBPC ...http://www.genengnews.com/news/bnitem.aspx?name=41873199 Insmed to Present at Biosimilars 2008 Conference - MSN MoneyCentral- September 15, 2008 RICHMOND, Va. , Sept. 15 PRNewswire-FirstCall -- Insmed Inc. INSM a developer of follow-on biologics and biopharmaceuticals, today announced that Geoffrey Allan , Ph.D., CEO of Insmed, will present at the Biosimilars 2008 Conference in Washington D ...http://news.moneycentral.msn.com/provider/providerarticle.aspx?feed=PR&date=20080915&a... Omrix Biopharmaceuticals to Webcast Presentation at UBS Global Life ... - MSN MoneyCentral- September 15, 2008 Omrix Biopharmaceuticals, Inc. ( Omrix ) OMRI , a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that Robert Taub, Chief Executive Officer, is scheduled to give a ...http://news.moneycentral.msn.com/provider/providerarticle.aspx?feed=BW&date=20080915&a... Mystic Pharmaceuticals CEO to Present At HHS BARDA Public Health ... - Phramalive.com- September 15, 2008 Mystic Pharmaceuticals President and CEO Timothy Sullivan will present at HHS BARDA STAKEHOLDERS WORKSHOP 2008 FOR PUBLIC HEALTH EMERGENCY MEDICAL COUNTERMEASURES, September 24-26, 2008 at the Crystal Gateway Marriott in Arlington, VA. The HHS Public ...http://www.pharmalive.com/News/Index.cfm?articleid=570865 Basic Cardiovascular Science - Researcher Receives 2008 European ... - Medical News Today- September 15, 2008 Regenerx Biopharmaceuticals, Inc. (AMEX:RGN) announced that Dr. Paul Riley, University College of London Institute of Child Health has been awarded the 2008 Outstanding Achievement Award of the European Society of Cardiology on Basic Cardiovascular ...http://www.medicalnewstoday.com/articles/121442.php |